- Home
- GECC vs LPTX Comparison
GECC vs LPTX Comparison
Compare GECC & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- LPTX
- Stock Information
- Founded
- GECC 2016
- LPTX 2011
- Country
- GECC United States
- LPTX United States
- Employees
- GECC N/A
- LPTX N/A
- Industry
- GECC Finance: Consumer Services
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GECC Finance
- LPTX Health Care
- Exchange
- GECC Nasdaq
- LPTX Nasdaq
- Market Cap
- GECC 116.9M
- LPTX 119.6M
- IPO Year
- GECC N/A
- LPTX N/A
- Fundamental
- Price
- GECC $10.85
- LPTX $0.34
- Analyst Decision
- GECC
- LPTX Buy
- Analyst Count
- GECC 0
- LPTX 2
- Target Price
- GECC N/A
- LPTX $8.00
- AVG Volume (30 Days)
- GECC 23.9K
- LPTX 369.6K
- Earning Date
- GECC 05-05-2025
- LPTX 05-20-2025
- Dividend Yield
- GECC 13.55%
- LPTX N/A
- EPS Growth
- GECC N/A
- LPTX N/A
- EPS
- GECC 0.42
- LPTX N/A
- Revenue
- GECC $42,909,000.00
- LPTX N/A
- Revenue This Year
- GECC $14.33
- LPTX N/A
- Revenue Next Year
- GECC N/A
- LPTX N/A
- P/E Ratio
- GECC $25.73
- LPTX N/A
- Revenue Growth
- GECC 18.13
- LPTX N/A
- 52 Week Low
- GECC $8.87
- LPTX $0.22
- 52 Week High
- GECC $11.39
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- GECC 67.15
- LPTX 40.84
- Support Level
- GECC $10.47
- LPTX $0.33
- Resistance Level
- GECC $10.25
- LPTX $0.38
- Average True Range (ATR)
- GECC 0.27
- LPTX 0.03
- MACD
- GECC 0.11
- LPTX -0.00
- Stochastic Oscillator
- GECC 91.31
- LPTX 13.64
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .